Details for Patent: 8,546,436

Which drugs does patent 8,546,436 protect, and when does it expire?

Patent 8,546,436 protects DUZALLO and ZURAMPIC and is included in two NDAs.

This patent has thirty-three patent family members in twenty-eight countries.

Summary for Patent: 8,546,436

Title:	Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)ace- tic acid and uses thereof
Abstract:	Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.
Inventor(s):	Treiber; Laszlo R. (San Diego, CA), Galvin; Gabriel (San Diego, CA), Zamansky; Irina (Oceanside, CA), Girardet; Jean-Luc (San Diego, CA)
Assignee:	Ardea Biosciences, Inc. (San Diego, CA)
Application Number:	13/339,283
Patent Claim Types: see list of patent claims	Compound; Use; Composition; Process;

Drugs Protected by US Patent 8,546,436

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ironwood Pharms Inc	DUZALLO	allopurinol; lesinurad	TABLET;ORAL	209203-001	Aug 18, 2017		DISCN	Yes	No				Y
Ironwood Pharms Inc	DUZALLO	allopurinol; lesinurad	TABLET;ORAL	209203-002	Aug 18, 2017		DISCN	Yes	No				Y
Ironwood Pharms Inc	ZURAMPIC	lesinurad	TABLET;ORAL	207988-001	Dec 22, 2015		DISCN	Yes	No			Y	Y

International Family Members for US Patent 8,546,436

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	084639
Australia	2011352129
Brazil	112013016982
Canada	2817249